Gamida Cell to delist as Highbridge takes full ownership
Israeli stem cell treatment company Gamida Cell (Nasdaq: GMDA) has announced that Highbridge Capital Management, the company's principal lender, will convert its $75 million bond into shares, and take the company private.…